文献速递心力衰竭与心肌病

射血分数降低心衰患者利钠肽应答与结局

Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

本研究基于GUIDE-IT试验,分析638例随机化后90天仍存活且有利钠肽检测结果的射血分数降低心衰患者。90天NT-proBNP≤1,000 pg/ml与更低的心血管死亡/心衰住院及全因死亡风险相关,且KCCQ评分更优。

要点

  • 90天NT-proBNP≤1,000 pg/ml者后续心衰住院/心血管死亡风险显著更低。
  • 该阈值达标与全因死亡风险降低及KCCQ总体评分改善相关。
  • 生物标志物指导组与常规治疗组达到该目标的比例无差异。

核心结论

  • 射血分数降低心衰患者在GDMT期间NT-proBNP降至≤1,000 pg/ml者结局更好。
  • 该发现可能有助于理解GUIDE-IT试验的结果。

研究设计与样本

  • GUIDE-IT试验的事后分析,纳入638例随机化后90天存活且NT-proBNP结果可用的受试者。
  • 分析随访期间心血管死亡/心衰住院或全因死亡率及KCCQ总体评分。

主要发现

  • 198例(31.0%)在90天时NT-proBNP≤1,000 pg/ml,生物标志物指导组与常规治疗组达标率无差异。
  • 90天NT-proBNP≤1,000 pg/ml与无心血管/心衰住院或全因死亡生存时间更长相关(两者p<0.001)。
  • 后续心衰住院/心血管死亡的校正风险比为0.26(95%CI 0.15-0.46,p<0.001),全因死亡风险比为0.34(95%CI 0.15-0.77,p=0.009)。
  • 无论基线浓度是否升高,90天NT-proBNP≤1,000 pg/ml均与更好结局及显著更优的KCCQ总体评分相关(p=0.02)。

关键数值与推荐

  • NT-proBNP目标值为1,000 pg/ml,为GUIDE-IT试验中探索的阈值。

临床怎么用

  • 可将GDMT期间NT-proBNP降至≤1,000 pg/ml作为评估治疗应答和预后的参考指标。

局限性

  • 为GUIDE-IT试验的事后分析,仅纳入90天存活且有NT-proBNP结果的受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. OBJECTIVES: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. METHODS: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. RESULTS: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). CONCLUSIONS: Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Januzzi JL, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019. PMID: 31466618. doi:10.1016/j.jacc.2019.06.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。